RAS MUTATION
Clinical trials for RAS MUTATION explained in plain language.
Never miss a new study
Get alerted when new RAS MUTATION trials appear
Sign up with your email to follow new studies for RAS MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced colorectal cancer: study tests smarter drug switch based on blood test
Disease control Recruiting nowThis study is for people with advanced colorectal cancer that has a certain genetic makeup (RAS/BRAF wild type) in the tumor but shows a different genetic change (RAS mutation) in a blood test. The goal is to see if a combination of chemotherapy (FOLFIRI) plus a drug called bevac…
Matched conditions: RAS MUTATION
Phase: PHASE3 • Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Disease control
Last updated May 17, 2026 00:42 UTC
-
New hope for hard-to-treat cancers: drug combo targets genetic weakness
Disease control Recruiting nowThis study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …
Matched conditions: RAS MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:42 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called RSC-1255, alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, pancreatic cancer, or glioblastoma) that have stopped responding to standard treatments. The goal is to find a safe dose and see if t…
Matched conditions: RAS MUTATION
Phase: PHASE1 • Sponsor: RasCal Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:40 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis early-phase study tests a new daily pill, AN9025, in people with advanced solid tumors that have specific RAS gene mutations. The main goals are to check the drug's safety and find the right dose. About 91 adults will take the drug daily and visit the clinic regularly for mo…
Matched conditions: RAS MUTATION
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New cancer pill enters first human safety trial
Disease control Recruiting nowThis is the first study in people testing an experimental pill called PAS-004 for advanced solid tumors that have specific genetic mutations (RAS, NF1, or RAF) or have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, …
Matched conditions: RAS MUTATION
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
Major study launches to unlock secrets of rare genetic disorders
Knowledge-focused Recruiting nowThis study aims to learn more about a group of genetic conditions called RASopathies, which affect development and can cause heart defects, learning problems, and cancer risk. Researchers will collect blood, tissue, and medical information from up to 1,000 participants, including…
Matched conditions: RAS MUTATION
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC